No Data
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Shengnuo Biology (688117): Rapid growth in Q3 performance, substantial order landing to boost medium and long-term development.
Q3 performance grew rapidly, with the three core sub-businesses showing overall stable development in 2024 Q1-3. The company achieved revenue of 0.338 billion yuan, a year-on-year increase of 16.00%; net income attributable to shareholders was 56.95 million yuan, a year-on-year increase of 63.66.
Shengnuo Biology (688117): A pioneer in the peptide field, overseas layout to create long-term growth space.
The company released the Q3 financial report for 2024, with a revenue of 0.139 billion yuan, an increase of 18.32% year-on-year, and a net income attributable to non-controlling interests of 34.53 million yuan, an increase of 144.80% year-on-year. Revenue for the first three quarters of 2024 reached 3 billion yuan.
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
No Data
No Data